logo
Plus   Neg
Share
Email

Biocon And Mylan's Biosimilar Trastuzumab Gets Approval In Brazil

Biosimilar Trastuzumab, co-developed by Biocon Ltd. and Mylan N.V. (MYL), has been approved by ANVISA, the Brazilian regulatory agency, through their partner Libbs Farmaceutica (Libbs), a leading Brazilian pharmaceutical company.

Co-developed by Biocon and Mylan, this is the first biosimilar Trastuzumab to be approved in Brazil and is indicated for the treatment of overexpressing HER2-positive metastatic breast cancer, HER2-positive early stage breast cancer and HER2-positive advanced gastric cancer.

Libbs will commercialize the product in Brazil under the brand name Zedora, which will provide affordable access to a cutting-edge biologics therapy for patients in Brazil.

For comments and feedback contact: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
After moving sharply lower in morning trading, stocks staged a substantial turnaround over the course of the trading session on Monday. The major averages climbed well off their worst levels of the day and into positive territory. Despite recently calling this year's $716 billion defense budget "crazy," President Donald Trump reportedly plans to ask for a sharp increase in military spending next fiscal year. Qualcomm Inc. said Monday that a Chinese court has granted the chipmaker's request for preliminary injunction against Apple Inc. in China, after finding that the tech giant has infringed on two patents held by Qualcomm. Qualcomm noted that the court has ordered an immediate ban on the import, sale and offers for Apple iPhone models in China.
Follow RTT